A Pooled Analysis of the Safety and Efficacy Results of the Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 3 REFINE-1 and REFINE-2 Trials of ATX-101, a Submental Contouring Injectable Drug for the Reduction of Submental Fat

2014 ◽  
Vol 134 ◽  
pp. 123 ◽  
Author(s):  
Steven H. Dayan ◽  
Derek H. Jones ◽  
Jean Carruthers ◽  
Shannon Humphrey ◽  
Fredric S. Brandt ◽  
...  
Keyword(s):  
Pooled Analysis ◽  
Phase 3 ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Injectable Drug ◽  
Submental Fat

REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction

2016 ◽  
Vol 42 (1) ◽  
pp. 38-49 ◽  
Author(s):  
Derek H. Jones ◽  
Jean Carruthers ◽  
John H. Joseph ◽  
Valerie D. Callender ◽  
Patricia Walker ◽  
...  
Keyword(s):  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Injectable Drug ◽  
Fat Reduction ◽  
Submental Fat

scholarly journals Spine Treatment Appraisal Report (STAR): Does Riluzole Improve Outcomes in Patients Undergoing Decompression Surgery for Degenerative Cervical Myelopathy?

2021 ◽  
pp. 219256822199740
Author(s):  
Joseph R. Dettori
Keyword(s):  
Cervical Myelopathy ◽  
Decompressive Surgery ◽  
Decompression Surgery ◽  
Phase 3 ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Double Blind Placebo ◽  
Degenerative Cervical Myelopathy

Fehlings MG, Badhiwala JH, Ahn H, et al. Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Neurol. 2020.

Sign in / Sign up

Export Citation Format

Share Document